The selling price and purchasing channels of Ensidipine

Enasidenib is an oral small molecule targeted drug mainly used to treat specific types of acute myeloid leukemia (AML). This drug is an isomeric cysteine synthase 2 (IDH2) inhibitor, targeting patients with Patients with AML with IDH2 gene mutations, especially relapsed or refractory AML patients.

Ensidipine has not yet obtained marketing approval in China, which means that domestic patients cannot purchase the drug directly and must seek overseas purchase channels. In foreign countries, relatively affordable drugs are generic drugs, especially those produced in Laos and Bangladesh, which sell for between 2,000 and 4,000 yuan. It is worth mentioning that there is almost no difference in the pharmaceutical ingredients between these generic drugs and the original drugs.

IDH2gene mutations are common in some AML patients. Such mutations can lead to abnormal activity of the IDH2 enzyme, thereby changing intracellular metabolic pathways and promoting abnormal proliferation and survival of leukemia cells. By inhibiting this abnormal IDH2enzyme activity, ensidipine blocks the production of abnormal metabolic pathways, thereby inhibiting the growth and proliferation of AML cells.

In clinical trials, ensidipine has shown significant efficacy. For AML patients carrying IDH2 mutations, ensidipine can help some patients achieve complete remission or partial remission and extend progression-free survival. This medication is usually taken by mouth once daily as monotherapy.

Although ensidipine has shown good efficacy in treatingAML, it may also cause some side effects. Common side effects include gastrointestinal discomfort (such as nausea, vomiting, diarrhea), abnormal liver function, bone marrow suppression, etc. Therefore, during treatment with ensidipine, patients need to be regularly monitored and evaluated by a physician to ensure the effectiveness and safety of the treatment.